Roche Pharmaceuticals China announced that China's State Drug Administration has officially approved Luoshijia® single-dose pre-filled injections for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular oedema secondary to retinal venous obstruction.

Zhitongcaijing · 3d ago
Roche Pharmaceuticals China announced that China's State Drug Administration has officially approved Luoshijia® single-dose pre-filled injections for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular oedema secondary to retinal venous obstruction.